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Abstract
Background: Paraplegia is the most devastating complication of thoracic or thoraco-abdominal aortic
surgery. During these operations, an ischemia-reperfusion process is inevitable and the produced radical
oxygen species cause severe oxidative stress for the spinal cord. In this study we examined the influence
of Amifostine, a triphosphate free oxygen scavenger, on oxidative stress of spinal cord ischemia-
reperfusion in rabbits.
Methods: Eighteen male, New Zealand white rabbits were anesthetized and spinal cord ischemia was
induced by temporary occlusion of the descending thoracic aorta by a coronary artery balloon catheter,
advanced through the femoral artery. The animals were randomly divided in 3 groups. Group I functioned
as control. In group II the descending aorta was occluded for 30 minutes and then reperfused for 75 min.
In group III, 500 mg Amifostine was infused into the distal aorta during the second half-time of ischemia
period. At the end of reperfusion all animals were sacrificed and spinal cord specimens were examined for
superoxide radicals by an ultra sensitive fluorescent assay.
Results: Superoxide radical levels ranged, in group I between 1.52 and 1.76 (1.64 ± 0.10), in group II
between 1.96 and 2.50 (2.10 ± 0.23), and in group III (amifostine) between 1.21 and 1.60 (1.40 ± 0.19) (p
= 0.00), showing a decrease of 43% in the Group of Amifostine. A lipid peroxidation marker measurement
ranged, in group I between 0.278 and 0.305 (0.296 ± 0.013), in group II between 0.427 and 0.497 (0.463 ±
0.025), and in group III (amifostine) between 0.343 and 0.357 (0.350 ± 0.007) (p < 0.00), showing a
decrease of 38% after Amifostine administration.
Conclusion: By direct and indirect methods of measuring the oxidative stress of spinal cord after
ischemia/reperfusion, it is suggested that intra-aortic Amifostine infusion during spinal cord ischemia phase,
significantly attenuated the spinal cord oxidative injury in rabbits.
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Paraplegia remains the most devastating complication
following descending thoracic or thoraco-abdominal aor-
tic surgery, with incidence rate from 4% to 33% [1]. It is
known that spinal cord ischemia from hypoperfusion
during temporary aorta cross clamping, as well as the sac-
rifice of some intercostals branches contributing to the
form of Adamkiewicz's artery, are the cause of this compli-
cation. The clinical evidence that some patients recover
with no neurological dysfunction only to develop
delayed-onset of paraplegia 1 to 5 day later, suggests that
some neurons remain viable after an ischemic attack but
may be at risk during reperfusion [2]. Recently it was dem-
onstrated that the mechanism of spinal cord injury after
ischemia-reperfusion consists of progressive loss of motor
neurons accompanied with a steady decline of motor
function [3]. The complexity of this mechanism is focused
to the alteration of the ratio between thromboxane and
prostacycline production, lipid peroxidation and reactive
oxygen species (ROS) production [4,5]. The ROS which
produced as a result of glutamate receptor-activated and
subsequently mediated pathways, initiates chain reactions
and damage cellular macromolecule, including proteins,
DNA and lipids, ultimately leading to cell death [6].
Although several endogenous antioxidant enzymes such
as superoxide dismutase, glutathione peroxidase, and cat-
alase can detoxify reactive oxygen species (ROS), the over-
production of the latter during the reperfusion of the
ischemic segment of spinal cord, can cause oxidative stress
followed by cell death [7]. Mechanical and pharmacolog-
ical methods have been studied but none has been proven
effective enough [8]. In studies, many molecular processes
have been investigated towards their intervention in spi-
nal cord injury-ischemia, implicating various cellular
mechanisms [9]. The reduction of ROS production has
always been at the top of this list.
Our hypothesis was that a ROS scavenger with specific
characteristics, such as S-2-3 aminopropylaminoethyl
phosphorothioic acid, might be infused during experi-
mentally produced temporary descending aorta ischemia
and might prevent the spinal cord ischemic cells from the
harmful effect of ROS production during the reperfusion
phase.
We used Amifostine (S-2-3 aminopropylaminoethyl
phosphorothioic acid, known as WR-2721), which has
been well documented to offer protection on normal cells
during radiotherapy and chemotherapy, particularly in
combination with cisplatin administration [10]. To the
best of our knowledge, there have been no other studies
investigating the direct or indirect protective effects of
Amifostine in spinal cord cells during ischemia-reper-
fusion injury.
Methods
Eighteen New Zealand white healthy male rabbits weigh-
ing 2.1 to 2.8 kg (mean 2.34 ± 0.17 Kg) were used in this
study. Animals were housed under Standard Conditions
and Guidelines for the Accommodation and Care of Ani-
mal used for experimental and other scientific purposes
(1999/575/EU) in the Animal Research Laboratory at Pat-
ras University.
Experimental Design/Groups
The animals were divided into three groups. Group I the
control group (n = 6): The animals underwent the surgical
procedure but the aorta was not occluded. Group II (n =
6): Aorta was occluded for 30 min, followed by reper-
fusion for 75 min. Group III (n = 6): Amifostine was
infused during the second half-time of aorta occlusion.
Animals with blood loss (>15 ml), arrythmia, or/and
hemodynamic instability (expressed with a decrease of BP
> 15 mmHg for more than 1 min), were excluded from the
experiment.
Antioxidant agent
Amifostine (ETHYOL®, Schering-Plough, Swiss) was the
anti-oxidant used factor. ETHYOL is the trihydrate form of
Amifostine known chemically as 2- [(3-aminopro-
pyl)amino]-ethanethiol dihydrogen phosphate
(WR2721). It is supplied as a sterile lyophilized powder
(10 ml vial contains 500 mg of Amifostine on the anhy-
drous basis) requiring reconstitution with normal saline
0.9% for intravenous infusion.
Oxidative stress detection reagent
As a detector of oxidative stress Hydroethidine (HYDRID-
INE®, Glaxo, Bristol, England) was used. This is a reduced
form of ethidium bromide [11,12].
Surgical procedure
The animals were fasted for 12 hours. Sedation was
induced by intramuscular Ketamine (KETAMINE
HYDROCHLORIDE®, Parke-Davis DIV of Warner-Lam-
bert, USA), (50 mg/kg), and Xylazine (XYLAZINE®, Bayer
HealthCare, Germany), (10 mg/kg) prior to the procedure
[13]. Animals' femoral site, back, tail and ears were pre-
pared before placed in supine position and allowed to
breathe spontaneously with O2 via face mask (FiO2 35%).
A 22-gauge venous catheter was placed in the marginal ear
vein and CEFAZOLINE SODIUM (VIFAZOLINE®, Vian-
nex, Greece), (10 mg/kg), was administered as a single
dose [14]. A 22-gauge catheter was placed in the central
ear artery. The experiment was recorded in 8 phases. Heart
Rate, Arterial Blood Pressure and O2 Saturation (Siemens,
SC 9000 XL) from the tail artery were monitored continu-
ously and recorded before starting the surgical procedure
(phase 1), after the insertion of the femoral arterial cathe-
ters (phase 2), after the insertion of the Peripheral Dilata-Page 2 of 12
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of the reagent (phase 7), and just before the end of the
experiment (phase 8). In addition, in groups (II) and (III)
measurements were recorded after aorta occlusion (phase
4), prior to release the occlusion (phase 5) and at the
onset of reperfusion (phase 6). Sedation was maintained
by intravenous administration of Propofol 1% (PROPO-
FOL®, Astra Zeneca, Chershire, UK), (0.6 mg/kg), and Fen-
tanyl (FENTANYL®, Sanofi, Sweden), (0.001-0.002 mg/
kg), periodically [15]. Ringer's Lactate (RINGER'S LAC-
TATE®, Mayrhofer Pharmakeutica Company) was infused
at a rate of 4-10 ml/kg/h, maintaining mean blood pres-
sure between 85 to 100 mmHg [16]. Placing a heating pad
under the animal and exposing it to a heat lamp main-
tained animal body temperature.
Arterial blood samples for partial pressure of O2 (PaO2),
partial pressure of CO2 (PaCO2), pH, full blood count
(FBC) and glucose measurements were obtained in all
groups prior to the surgical procedure (phase 1), 15 min
after the administration of the reagent (phase7), and just
before the end of the experiment (phase 8). Serum Ca2+
level measured in all groups at the onset (phase 1) and at
the end of the experiment (phase 8).
After the rabbit had been stabilized and heparinized with
(150 U/kg) Heparin Sulfate (10 U/ml) (HEPARIN SUL-
FATE®, Leo Pharmaceutical, Denmark), its femoral arteries
were isolated and cannulated bilaterally with a 22-gauge
catheter. The right one was used for the purpose of moni-
toring the peripheral blood pressure during the experi-
ment. At the left side, a 5.5FR Peripheral Dilatation
Catheter with microglide Coating (AGIL/TRAC .035 GUI-
TANT CORPORATION, Santa Clara, USA) was introduced
over a guide-wire, using Seldinger technique. The catheter
was advanced to the descending aorta up to the level of
left subclavian artery. The level had been estimated in a
previous experiment with an open procedure and percuta-
neous angiography [17]. After that, solution of 0.5 ml of
Sodium Heparin (10 U/ml) in 10 ml normal saline 0.9%
was used for the protection of the catheter.
Peripheral Dilatation Catheter balloon was inflated by the
insertion 0.5 ml water for Injection (8 Atm) and aorta
occlusion was established for 30 min. Aorta occlusion was
verified by the decrease of blood pressure via the arterial
catheter in the opposite femoral artery and also by the
increase of blood pressure via the ear arterial catheter.
Amifostine was infused via the Peripheral Dilatation
Catheter line intra-aortically and proximally to the
occluded segment, 15 min prior to the release of aorta
occlusion by deflation of the balloon. When 30 min of
aorta occlusion was completed, the balloon was deflated
and aortic perfusion was restored. For oxidative stress
detection, HE reagent was slowly administered (for 4
min) intra-aortically via the Peripheral Dilatation Cathe-
ter line, by the onset of reperfusion. After 75 min of reper-
fusion the animals were sacrificed with lethal doses of
Propofol and Fentanyl [15]. Rapid (<2 min) laminectomy
was performed by using rib shears (24-101-22 MARTIN,
Tuttlingen, Germany), and lumbar spinal cord was har-
vested, 2 cm distally to 12th rib.
Animal treatment
Amifostine (ETHYOL), 500 mg (initially dissolved in 10
ml normal saline 0.9%), was administered to the rabbits
as a 15-minute intravenous infusion starting 15 minutes
after the aorta occlusion (total duration 30 min) through
the tip of the peripheral dilatation catheter proximally
into the aorta.
Hydroethidine, 4.7 mg/Kg was administered intra-aorti-
cally in the descending thoracic aorta (just after the sub-
clavian artery origin), (in 1 ml solution) to the rabbits, via
the Peripheral Dilatation Catheter immediately after
deflation of the balloon.
Tissue treatment
Rabbit spinal cord was homogenized with a 2-ml glass-
glass Potter-Elvehjem homogenizer in 1:1 tissue wet
weight: volume ice-cold phosphate buffer (50 mM, pH
7.8, containing 10 mM sodium cyanide).
Superoxide radical assay
The method is based on the reaction between superoxide
radical and Hydroethidine that results in the formation of
the specific product 2-OH-ethidium, the formation rate of
which is measured and converted to superoxide radical
production rate [18]. 2-OH-Ethidium is estimated after
being extracted from the tissue in alkaline acetone, iso-
lated via cation and hydrophobic microcolumn chroma-
tographies and quantified by the use of its fluorescence
properties before and after consumption of 2-OH-ethid-
ium by a horsradish peroxidase (HRP)/H2O2 system (in
the presence of DNA). Fluorescence measurements were
performed in a quartz microcuvette (internal dimensions
4 × 4 × 45 mm) with its appropriate holder and a Shi-
madzu RF-1501 spectrofluorometer set at 10 nm excita-
tion/emission slit width and high sensitivity. Superoxide
radical concentration is expressed in pmole mg-1 protein
(in 75 min).
Lipid peroxidation TBARS assay
Spinal cord homogenate was assayed by a modified thio-
barbituric acid (TBA)-based method [19]. Specifically, up
to 0.15 ml sample was mixed with 0.15 ml TBA reagent
[0.5% w/v TBA in 20% w/v trichloroacetic acid (TCA) and
0.33 N HCl]. To the resulting mixture was added 2 μl 2%
(w/v) of the lipid antioxidant butyl-hydroxyl anisole
(BHA, made in absolute ethanol) to prevent artificial lipid
peroxidation production during the assay. The mixturePage 3 of 12
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temperature. To that 0.3 ml isobutanol was added, mixed
by vigorous vortexing, centrifuged at 15000 g for 3 min,
and the fluorescence of the upper butanol layer was meas-
ured at excitation 535 and emission 550 nm against buta-
nol-treated sample and reagent blanks (0.15 ml sample
plus 0.15 ml 20% TCA containing 0.33 N HCl and 0.02%
w/v BHA, and 0.15 ml homogenate-buffer plus 0.15 ml
TBA reagent containing 0.02% w/v BHA, respectively).
Emission fluorescence was converted to malondialdehyde
(MDA) equivalents from a standard curve using malonal-
dehyde bis(dimethyl acetal) (0-2 nM). Measurements
were done in a Shimadzu RF-1501 spectrofluorophotom-
eter set at low sensitivity and excitation/emission band-
width 10 nm. TBARS were expressed in fmol MDA
equivalents mg-1 total protein.
Protein concentration assay
Protein in ~200× diluted sample homogenates was deter-
mined by a modification of a CBB-based method [20].
Specifically, 0.063 ml of the homogenate was mixed with
0.02 ml 0.5% (v/v) Triton X-100 and 0.017 ml 6 N HCl.
The mixture was incubated at 100°C for 10 min, brought
to room temperature and mixed with 0.9 ml 0.033% (w/
v) CBB-G250 stock reagent (made in 0.5 N HCl, stirred for
30 min and filtrated through Whatman #1 filter paper by
water pump aspiration, and stored in dark) and incubated
for 5 min at room temperature. The absorbance of the
mixture at 620 nm was converted to protein mg from a 0-
0.05 mg BSA standard curve (against appropriate sample
and reagent blanks). A Shimadzu UV-VIS 1201 spectro-
photometer was used.
Statistical Analysis
Data represent mean ± one standard deviation. Statistical
analysis was carried out using SPSS for Windows software
program version 13.0. A single factor analysis of variance
(ANOVA) was performed to check for differences between
the three animal subgroups. The comparisons of the dif-
ferences in vital signs and blood investigations within the
same group were performed by single factor analysis of
variance (ANOVA) with post hoc comparisons (Tukey-
Scheffe-Student Newman Keuls Tests) and among the dif-
ferent groups by the One Way Multivariate ANOVA test.
Wilcoxon paired sample test was also used to compare
two paired data in the same group. Unpaired Student's t-
test was performed for the non-parametrically analysis of
neurological function score. Differences were considered
significant at a P value of < 0.05.
Results
All rabbits survived until time of sacrifice without signifi-
cant hemodynamic derangements or other complications.
Therefore, additional drug support treatment was not con-
sidered necessary during the experiment.
Clinical outcome
Hind limb paralysis was noticed in all animals of Group
II. The administration of Amifostine (Group III)
improved neurological status because all animals were
able to use their hind limbs. Their ability to hop couldn't
be assessed due to short period of anesthetic recovery.
Vital signs
No statistical significant differences in heart rate and O2
saturation were noted during the procedure in each group
and among the groups (p > 0.05). Between the phases of
the experiment, as well as during the slow infusion of
Amifostine and reagent Hydroethidine infusion, blood
pressure records did not show any statistical difference
among three groups. However, there was a significant sta-
tistical difference between the phases in the Group II and
Group III with (p = 0.000), which was attributed to the
aortic clamping.
Blood gases
From blood gases measurements there was no difference
in pH among the groups but significant statistical differ-
ence was recorded in the Group II among the phases (p =
0.01). In this group there was a decrease in blood pH just
after the aorta release (7.34 ± 0.048) as compared to (7.44
± 0.061) and (7.40 ± 0.042) at the onset (phase 1) and at
the end of the experiment (phase 8), respectively.
No statistical difference was obtained in pO2 and pCO2 in
the groups and between the groups with an exception in
Group III in which, a decrease of pCO2 (30.91 ± 7.9) was
observed at the end of the experiment (phase 8) as com-
pared to the other phases (phase1 and phase7) of the
experiment (43.56 ± 5.2 and 45.08 ± 9.20), respectively
with p = 0.01.
Of note, there was a statistically significant difference (p =
0.005) between the groups concerning the HCO3 - levels,
whilst this was not observed within the same group (Fig-
ure 1).
Blood tests
Blood results tests obtained at the onset of the procedure,
after the aorta release and the administration of the agent
and at the end of the experiment revealed the following:
1) No statistically significant difference was observed in
Ht between the groups (p = 0.058) although there was a
difference among the same group, probably due to some
blood loss during the operating procedure. 2) Statistically
significant decrease in WBC of Groups III and II was
observed as compared to Group I (p = 0.01) (Figure 2). 3)
Statistically significant decrease in the PLTs of Group II
was observed as compared with Group I and Group III (p
= 0.01), although there was no statistical difference within
the same group [(p(I) = 0.902, p(II) = 0.136, p(III) =Page 4 of 12
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serum glucose value throughout the experiment.
Serum calcium levels were significantly (p = 0.001)
reduced at the end of the experiment in all groups (phase
8), with a significant decrease of 25% in Group III of Ami-
fostine (Figure 4).
Superoxide radical assay
The superoxide radical assay revealed an increase of
27.43% in superoxide free radical formation in the spinal
cord of the ischemic rabbits, which was decreased by
42.68% [as much as 15.25% below the Group(I)] by Ami-
fostine administration (Table 1), (Figure 5). Statistically
significant difference was found among the groups (p =
0.000).
TBARS assay
Lipid peroxidation marker TBARS assay results showed an
increase in peroxidation production of 55.3% in Group II,
which was decreased by 35.3% after Amifostine adminis-
tration in Group III (Table 2, Figure 6). Statistical analysis
showed a significant difference (p = 0.000).
Discussion
For descending thoracic or thoraco-abdominal aorta pro-
cedures, during which reduced local tissue perfusion and
oxygenation compromise spinal cord function, paraplegia
has been considered as the most devastating complication
[1,2,21].
The most immediate event at the neuronic cellular level
during ischemia, is the depolarization and the consequent
opening of voltage-depended ion channels (i.e., Na+, K+,
Ca+) [22]. This leads to massive release of a variety of
neuro-transmitters including glutamate receptor-operated
ion channels. The most important consequence of these
rapidly evolving ionic disturbances is the accumulation of
intracellular Ca+, which initiates several damaging effects/
actions. These include [22-24]: a) mitochondrial dysfunc-
tion, leading to a failure of aerobic energy metabolism
and lactate accumulation, b) activation of mitochondrial
and cytoplasmic nitric oxide synthase (NOS) and produc-
tion of nitric oxide [25], c) activation of phospholipase
A2, which liberates arachidonic acid (AA), which is then
converted by cyclooxygenases (COX 1,2) to a number of
deleterious prostanoids and by lipoxygenases (LTs) some
HCO3 levelsFigure 1
HCO3 levels. HCO3 levels graphics shows a decrease in Group III.
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leukocyte and macrophage influx, and) activation of the
calcium-activated cysteine protease calpain which is
mediating axonal damage in SCI.
One of the consequences of mitochondrial dysfunction,
COX and lipoxygenase activity and NOS activation is the
formation of reactive oxygen species (ROS), including
peroxynitrite anion (ONOO-), a product of superoxide
radical reaction with nitric oxide [26].
ROS are capable of independent existence. The O2 toxicity
is due to excess formation of the superoxide radical (O2 -),
a product of the single electron reduction of molecular
oxygen [26]. Having too many ROS in relation to the
available antioxidants is considered as a state of high oxi-
dative stress, which can cause biomolecular damage.
Severe oxidative damage, especially to DNA, may trigger
activation of the cysteine protease caspase-3 and conse-
quently death by apoptosis. The onset of apoptosis in oli-
godendroglia, distant to the site of injury, appears to be
unique in acute spinal cord ischemia and contributes to
axonal demyelination and dysfunction with long-term
neurological deficits.
On the other hand, peroxynitrite anion (ONOO-) is capa-
ble of causing widespread damage to lipids, proteins and
nucleic acids [26]. From these, cell membrane lipid perox-
idation has been conclusively demonstrated to be a key
mechanism triggering cellular damage. This includes:
decreased membrane fluidity which makes it easier for
phospholipids to exchange between the two halves of the
bilayer, increased membrane leaking to substances that
do not normally cross it other than through specific chan-
nels (e.g. K+ and Ca2+), and damaged membrane proteins
and inactivated receptors, enzymes, and ion chan-
White blood cells count samplesFigure 2
White blood cells count samples. Note the statistically significant decrease (p = 0.01) of WBCs in Groups (III) and (II) 
compared with Group (I).
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and their fragmentation to produce aldehydes will even-
tually lead to loss of membrane integrity, e.g. rupture of
lysosomal or central vacuolar membranes. [27,28]
The importance of a treatment strategy is to identify and
administer an agent, which can act effectively as a target in
the biochemical cascade of apoptosis. This must be a com-
petitive caspase inhibitor with increased cell permeability
and sufficient active intra-cellular metabolite level. We
showed experimentally by this study that, the organic tri-
ophosphate agent Amifostine or WR-2721 appears to be
very effective in the reduction of ROS levels produced in
spinal cord cells during ischemia-reperfusion injury.
This drug and its trihydrate form is a pro-drug that is
dephosphorylated in tissues to a pharmacologically active
free thiol. Clinical pharmacokinetic studies showed that it
is rapidly cleared from the plasma with a distribution half
life of <1 min and an estimated elimination half-life of
approximately 8 min. This means that only 10% of
ETHYOL remains in the plasma for 6 min after drug
administration. In fact, within 15 min after administra-
tion it is hydrolyzed by either membrane-bound acid
phosphatase or alkaline phosphatase to produce the cor-
responding free sulfhydryl metabolite WR-1065 [29]. In
contrast to the brief plasma half-life, Amifostine and its
metabolites are present at maximal levels in tissues
between 5 to 15 min following the injection and they also
remain intracellularly for long time.
A major advantageous property of Amifostine and its cor-
responding free thiol WR-1065 is the ability to scavenge
free radicals, and to affect cellular DNA repair enzymes
and the cell cycle progression. Therefore, this drug is con-
sidered as a radioprotective and chemoprotective agent,
Platelets countFigure 3
Platelets count. A decrease in PLTs is noticed in Group (II) compared with Groups (I) and (III).
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properties [30]. In addition, it has also been shown that
Amifostine can normalize hypercalcemia through its
PTH-independent inhibitory effect on TRCa. The key role
for this effect is attributed probably to its phosphate group
that bounds to or is liberated from the molecule within
the extra- and/or intracellular space [31,32].
The effectiveness of Amifostine appears to be related to its
high affinity for DNA, to the similarity in structure of
phosphorothioate metabolites to polyamines, and to its
effects on processes related to DNA structure and synthe-
sis [33]. Indeed, Amifostine induces the DNA-binding
activity of wild-type p53, with its most important bio-
chemical function being the activation of genes involved
in control of the cell cycle, apoptosis, cellular differentia-
tion and DNA repair [34,35] (Figure 7). In the present
study, we have shown that Amifostine can also be protec-
tive in the reduction of oxidative stress induced to the spi-
nal cord cells during ischemia-reperfusion, namely under
conditions of descending thoracic or thoraco-abdominal
Serum Calcium levelsFig re 4
Serum Calcium levels. Serum Calcium was measured at the onset (Ca-1) and at the end of the experiment (Ca-8). It's 
noticed a decrease in Ca levels of 5.5% and 8% in (I) and (II) groups and 25% in (III) (animals 13 to 18).
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Table 1: Superoxide radical assay
N Control Aorta occlusion Amifostine
1 1.76 2.1 1.4
2 1.72 2.05 1.6
3 1.52 2.5 1.21
4 1.63 1.91 1.3
5 1.57 1.96 1.45
6 1.62 2 1.4
Mean ± SD 1.64 ± 0.09 2.09 ± 0.21 1.39 ± 0.13
Expressed as % 100 127.43 84.75
Superoxide radical assay. Superoxide radical (in pmole mg-1 protein 
for 75 min). † When a mean value appears it is followed by a standard 
deviation. ††Taking as 100% the mean value of the control group.Page 8 of 12
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27.43% in the spinal cord of ischemic rabbits and a signif-
icant 42.68% decrease in the Amifostine group is a direct
proof of the development of oxidative stress during aorta
occlusion, followed by it's a significant remission after the
agent administration. Moreover, oxidative stress was
shown indirectly by a 55.3% increase of the lipid peroxi-
dation marker TBARS, followed by a 35.3% significant
decrease caused by Amifostine.
Amifostine and its active metabolites seems to be "neuro-
protective" factors during spinal cord ischemia, and could
be usable in the corresponding operations of thoracic
aorta, after clarification (or elucidation) of dose and
Superoxide radical assayFigu e 5
Superoxide radical assay. The superoxide radical assay revealed a statistical significant increase (p = 0.000) of 27.43% in 
superoxide free radical formation in the spinal cord of the ischemic rabbits (Group II) compare to controls (Group I). The val-
ues of superoxide radical assay in amifostine group were preserved.
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Table 2: Thibarbituric acid reactive species (TBARS) assay
N Control Aorta occlusion Amifostine
1 0.28 0.497 0.357
2 0.31 0.427 0.343
3 0.31 0.470 0.349
4 0.29 0.465 0.35
5 0.30 0.455 0.344
6 0.30 0.480 0.347
Mean ± SD 0.30 ± 0.01 0.466 ± 0.024 0.360 ± 0.005
Expressed as % 100 155.3 120
Thibarbituric acid reactive species (TBARS) assay (in fmole mg-1 protein). † When a mean value appears it is followed by a standard deviation. 
††Taking as 100% the mean value of control group.Page 9 of 12
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tive to the neuro-cellular damage exposure is critical and
the effectiveness of the compound is strongly related to
pharmacokinetic properties of the molecule. Having
taken into consideration the pharmacokinetic parameters
of Amifostine, we managed to achieve the highest concen-
tration of its active metabolite during the time of free rad-
ical accumulation in spinal cord cells, by intra-aortic
administration, just prior to the release of the aortic occlu-
sion. In our opinion, this maneuver allows the agent to
scavenge ROS, as early as possible in their generation, and
before the onset of their harmful effect. It is quite interest-
ing to be mentioned that according to the results of the
superoxide radical assay, oxidative stress was decreased
even below control levels (by 15.25%), suggesting that
Amifostine may start its activity against ROS production,
before release of aortic occlusion, resulting to maximum
spinal cord cell protection.
There are some limitations in our study. This experimen-
tal study has been designed as an "acute experiment",
focused on the "quantity" of produced oxidative stress of
spinal cord, under conditions mimicking descending tho-
racic aorta operations. We did not design the study for
clinical observation of neurologic complications of spinal
cord ischemia. It is well known, that these complications
can develop several days (till 7) after ischemia, and even-
tual measurement of oxidative stress at this time, could be
unreliable. In addition, the re-agent we used for free radi-
cals detection has an acting-time limitation of 75 minutes.
As the positive results of the effectiveness of Amifostine as
scavenger of free radicals in spinal cord after ischemia-
reperfusion injury have been proved, we have planned the
extension of the experiment with focus to the post opera-
tive neurological status of the animals.
Conclusion
In conclusion, the results of our study indicate that intra-
aortic Amifostine (WR-2721) infusion during temporary
thoracic aorta occlusion has a significant beneficial
"neuro-protective" effect in the protection of spinal cord
of rabbits. Further studies are needed to clarify the poten-
Lipid peroxidation assayFigure 6
Lipid peroxidation assay. TBARS assay demonstrate a statistical significant increase in peroxidation production of 55.3% in 
Group II compare to controls (Group I). The amifostine administration (Group III) decreased the lipid peroxidation by 35.3%. 
TBARS: thiobarbituric acid reactive species.
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Oxidative stress and AmifostineFigure 7
Oxidative stress and Amifostine. The diagram demonstrates the cell damage when oxidative stress occurred and the Ami-
fostine protective and repair effects after its activation into cell and nuclear. Straight lines denote the oxidative stress mecha-
nism. Dot lines denote Amifostine points of effect.
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Journal of Cardiothoracic Surgery 2009, 4:50 http://www.cardiothoracicsurgery.org/content/4/1/50tial application of this "neuro-protective" factor in human
beings, during the operations on the descending or tho-
raco-abdominal aorta.
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